Related Experiment Video

Updated: Jun 28, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

Identification of KDM4C as a gene conferring drug resistance in multiple myeloma

Na Zhang1,2, Ruilong Lan3, Yingyu Chen1

  • 1Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, 350001, China.

Open Life Sciences
|April 16, 2024
PubMed

Insights

This study identifies KDM4C as a key driver of bortezomib (BTZ) resistance in multiple myeloma (MM). Inhibiting KDM4C may restore sensitivity to BTZ, offering a new strategy for treating resistant MM patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Bortezomib (BTZ) is a crucial proteasome inhibitor for multiple myeloma (MM).
  • Drug resistance to BTZ leads to disease relapse and poor patient prognosis.
  • Identifying mechanisms of BTZ resistance is critical for improving MM treatment outcomes.

Purpose of the Study:

  • To identify novel genes contributing to BTZ resistance in multiple myeloma.
  • To investigate the functional role of identified genes in mediating BTZ resistance.
  • To explore KDM4C as a potential therapeutic target for overcoming BTZ resistance.

Main Methods:

  • Screening of 26 genes associated with drug resistance in MM cell lines.
  • Quantitative analysis of gene expression in BTZ-sensitive versus BTZ-resistant MM cells.
  • Functional studies involving KDM4C overexpression and knockdown (using shRNA) in MM cells.

Main Results:

  • KDM4C expression was significantly elevated in BTZ-resistant MM cells compared to sensitive cells.
  • Overexpression of KDM4C increased MM cell tolerance to BTZ.
  • Knockdown of KDM4C sensitized BTZ-resistant MM cells to BTZ treatment.

Conclusions:

  • KDM4C plays a critical role in conferring resistance to bortezomib in multiple myeloma.
  • KDM4C represents a promising therapeutic target for overcoming BTZ resistance in MM.
  • Targeting KDM4C could offer a novel strategy to improve treatment efficacy for relapsed or refractory MM.
Keywords:
KDM4Cbortezomibdrug resistancehematologic cancermultiple myelomaproteasome inhibitors

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

7.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K